{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T12:13:58Z","timestamp":1793708038680,"version":"4.6.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,2,27]],"date-time":"2023-02-27T00:00:00Z","timestamp":1677456000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,2,27]],"date-time":"2023-02-27T00:00:00Z","timestamp":1677456000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["KWF UL-2014-6831"],"award-info":[{"award-number":["KWF UL-2014-6831"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["KWF UL-2014-6831"],"award-info":[{"award-number":["KWF UL-2014-6831"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["KWF UL-2014-6831"],"award-info":[{"award-number":["KWF UL-2014-6831"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["KWF UL-2014-6831"],"award-info":[{"award-number":["KWF UL-2014-6831"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["KWF UL-2014-6831"],"award-info":[{"award-number":["KWF UL-2014-6831"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["KWF UL-2014-6831"],"award-info":[{"award-number":["KWF UL-2014-6831"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["KWF UL-2014-6831"],"award-info":[{"award-number":["KWF UL-2014-6831"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["KWF UL-2014-6831"],"award-info":[{"award-number":["KWF UL-2014-6831"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["KWF UL-2014-6831"],"award-info":[{"award-number":["KWF UL-2014-6831"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["KWF UL-2014-6831"],"award-info":[{"award-number":["KWF UL-2014-6831"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["KWF UL-2014-6831"],"award-info":[{"award-number":["KWF UL-2014-6831"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["KWF UL-2014-6831"],"award-info":[{"award-number":["KWF UL-2014-6831"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["KWF UL-2014-6831"],"award-info":[{"award-number":["KWF UL-2014-6831"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["KWF UL-2014-6831"],"award-info":[{"award-number":["KWF UL-2014-6831"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The immunoglobulin J chain (Jchain) is highly expressed in the majority of multiple myeloma (MM), and Jchain-derived peptides presented in HLA molecules may be suitable antigens for T-cell therapy of MM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Using immunopeptidomics, we identified Jchain-derived epitopes presented by MM cells, and pHLA tetramer technology was used to isolate Jchain-specific T-cell clones.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We identified T cells specific for Jchain peptides presented in HLA-A1, -A24, -A3, and -A11 that recognized and lysed\n                      <jats:italic>JCHAIN<\/jats:italic>\n                      -positive MM cells. TCRs of the most promising T-cell clones were sequenced, cloned into retroviral vectors, and transferred to CD8 T cells. Jchain TCR T cells recognized target cells when\n                      <jats:italic>JCHAIN<\/jats:italic>\n                      and the appropriate HLA restriction alleles were expressed, while\n                      <jats:italic>JCHAIN<\/jats:italic>\n                      or HLA-negative cells, including healthy subsets, were not recognized. Patient-derived\n                      <jats:italic>JCHAIN<\/jats:italic>\n                      -positive MM samples were also lysed by Jchain TCR T cells. In a preclinical in vivo model for established MM, Jchain-A1, -A24, -A3, and -A11 TCR T cells strongly eradicated MM cells, which resulted in 100-fold lower tumor burden in Jchain TCR versus control-treated mice.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>We identified TCRs targeting Jchain-derived peptides presented in four common HLA alleles. All four TCRs demonstrated potent preclinical anti-myeloma activity, encouraging further preclinical testing and ultimately clinical development.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13045-023-01408-6","type":"journal-article","created":{"date-parts":[[2023,2,27]],"date-time":"2023-02-27T07:02:49Z","timestamp":1677481369000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Broadly applicable TCR-based therapy for multiple myeloma targeting the immunoglobulin J chain"],"prefix":"10.1186","volume":"16","author":[{"given":"Miranda H.","family":"Meeuwsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne K.","family":"Wouters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tassilo L. A.","family":"Wachsmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renate S.","family":"Hagedoorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel G. D.","family":"Kester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis F. G.","family":"Remst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk M.","family":"van der Steen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnoud H.","family":"de Ru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Els P.","family":"van Hees","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martijn","family":"Kremer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marieke","family":"Griffioen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter A.","family":"van Veelen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. H. Frederik","family":"Falkenburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirjam H. M.","family":"Heemskerk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,27]]},"reference":[{"issue":"15","key":"1408_CR1","doi-asserted-by":"publisher","first-page":"8039","DOI":"10.1200\/JCO.2019.37.15_suppl.8039","volume":"37","author":"B Nandakumar","year":"2019","unstructured":"Nandakumar B, Binder M, Dispenzieri A, Kapoor P, Buadi F, Gertz MA, et al. Continued improvement in survival in multiple myeloma (MM) including high-risk patients. J Clin Oncol. 2019;37(15):8039.","journal-title":"J Clin Oncol"},{"issue":"18","key":"1408_CR2","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","volume":"380","author":"N Raje","year":"2019","unstructured":"Raje N, Berdeja J, Lin Y, Siegel D, Jagannath S, Madduri D, et al. Anti-BCMA CAR T-Cell therapy bb2121 in relapsed or refractory multiple myeloma. N Engl J Med. 2019;380(18):1726\u201337.","journal-title":"N Engl J Med"},{"issue":"1","key":"1408_CR3","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s13045-018-0681-6","volume":"11","author":"WH Zhao","year":"2018","unstructured":"Zhao WH, Liu J, Wang BY, Chen YX, Cao XM, Yang Y, et al. A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma. J Hematol Oncol. 2018;11(1):141.","journal-title":"J Hematol Oncol"},{"issue":"10297","key":"1408_CR4","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","volume":"398","author":"JG Berdeja","year":"2021","unstructured":"Berdeja JG, Madduri D, Usmani SZ, Jakubowiak A, Agha M, Cohen AD, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study. Lancet. 2021;398(10297):314\u201324.","journal-title":"Lancet"},{"issue":"6","key":"1408_CR5","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1172\/JCI126397","volume":"129","author":"AD Cohen","year":"2019","unstructured":"Cohen AD, Garfall AL, Stadtmauer EA, Melenhorst JJ, Lacey SF, Lancaster E, et al. B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma. J Clin Investig. 2019;129(6):2210\u201321.","journal-title":"J Clin Investig"},{"issue":"1","key":"1408_CR6","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1038\/s41467-021-21177-5","volume":"12","author":"MK Samur","year":"2021","unstructured":"Samur MK, Fulciniti M, Aktas Samur A, Bazarbachi AH, Tai YT, Prabhala R, et al. Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma. Nat Commun. 2021;12(1):868.","journal-title":"Nat Commun"},{"issue":"10","key":"1408_CR7","doi-asserted-by":"publisher","first-page":"5517","DOI":"10.4049\/jimmunol.167.10.5517","volume":"167","author":"A Bouchon","year":"2001","unstructured":"Bouchon A, Cella M, Grierson HL, Cohen JI, Colonna M. Activation of NK cell-mediated cytotoxicity by a SAP-independent receptor of the CD2 family. J Immunol. 2001;167(10):5517\u201321.","journal-title":"J Immunol"},{"issue":"485","key":"1408_CR8","doi-asserted-by":"publisher","first-page":"7746","DOI":"10.1126\/scitranslmed.aau7746","volume":"11","author":"EL Smith","year":"2019","unstructured":"Smith EL, Harrington K, Staehr M, Masakayan R, Jones J, Long TJ, et al. GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells. Sci Transl Med. 2019;11(485):7746.","journal-title":"Sci Transl Med"},{"issue":"2","key":"1408_CR9","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.ymthe.2021.08.010","volume":"30","author":"MH Meeuwsen","year":"2022","unstructured":"Meeuwsen MH, Wouters AK, Jahn L, Hagedoorn RS, Kester MGD, Remst DFG, et al. A broad and systematic approach to identify B cell malignancy-targeting TCRs for multi-antigen-based T cell therapy. Mol Ther J Am Soc Gene Ther. 2022;30(2):564\u201378.","journal-title":"Mol Ther J Am Soc Gene Ther"},{"issue":"6","key":"1408_CR10","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1111\/j.1365-3083.2009.02319.x","volume":"70","author":"P Brandtzaeg","year":"2009","unstructured":"Brandtzaeg P. Mucosal immunity: induction, dissemination, and effector functions. Scand J Immunol. 2009;70(6):505\u201315.","journal-title":"Scand J Immunol"},{"key":"1408_CR11","unstructured":"Xu AQ, Barbosa RR, Calado DP. <em>Jchain<\/em>-driven cre enables specific genetic manipulation and timestamping of plasma cell in their niche. bioRxiv. 2020:2020.04.12.038380."},{"issue":"2","key":"1408_CR12","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1111\/j.1365-2249.1992.tb02981.x","volume":"87","author":"DE Nilssen","year":"1992","unstructured":"Nilssen DE, Brandtzaeg P, Fr\u00f8land SS, Fausa O. Subclass composition and J-chain expression of the \u201ccompensatory\u201d gastrointestinal IgG cell population in selective IgA deficiency. Clin Exp Immunol. 1992;87(2):237\u201345.","journal-title":"Clin Exp Immunol"},{"issue":"4","key":"1408_CR13","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/0002-9343(90)90500-D","volume":"88","author":"HM Lokhorst","year":"1990","unstructured":"Lokhorst HM, Dekker AW, Baarlen JV, Bast EJ. J chain disease: an aggressive evolution of multiple myeloma. Am J Med. 1990;88(4):417\u201320.","journal-title":"Am J Med"},{"issue":"3","key":"1408_CR14","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/BF00710071","volume":"405","author":"G Kel\u00e9nyi","year":"1985","unstructured":"Kel\u00e9nyi G. Intracellular J chains in lymphoproliferative diseases. Virchows Archiv A. 1985;405(3):365\u201378.","journal-title":"Virchows Archiv A"},{"issue":"6","key":"1408_CR15","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/nri3667","volume":"14","author":"L Klein","year":"2014","unstructured":"Klein L, Kyewski B, Allen PM, Hogquist KA. Positive and negative selection of the T cell repertoire: what thymocytes see (and don\u2019t see). Nat Rev Immunol. 2014;14(6):377\u201391.","journal-title":"Nat Rev Immunol"},{"issue":"17","key":"1408_CR16","doi-asserted-by":"publisher","first-page":"5615","DOI":"10.1158\/1078-0432.CCR-11-1066","volume":"17","author":"AL Amir","year":"2011","unstructured":"Amir AL, van der Steen DM, van Loenen MM, Hagedoorn RS, de Boer R, Kester MD, et al. PRAME-specific Allo-HLA-restricted T cells with potent antitumor reactivity useful for therapeutic T-cell receptor gene transfer. Clin Cancer Res Off J Am Assoc Cancer Res. 2011;17(17):5615\u201325.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"44","key":"1408_CR17","doi-asserted-by":"publisher","first-page":"71536","DOI":"10.18632\/oncotarget.12247","volume":"7","author":"L Jahn","year":"2016","unstructured":"Jahn L, Hagedoorn RS, van der Steen DM, Hombrink P, Kester MG, Schoonakker MP, et al. A CD22-reactive TCR from the T-cell allorepertoire for the treatment of acute lymphoblastic leukemia by TCR gene transfer. Oncotarget. 2016;7(44):71536\u201347.","journal-title":"Oncotarget"},{"issue":"10","key":"1408_CR18","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1182\/blood-2009-03-209387","volume":"114","author":"S Wilde","year":"2009","unstructured":"Wilde S, Sommermeyer D, Frankenberger B, Schiemann M, Milosevic S, Spranger S, et al. Dendritic cells pulsed with RNA encoding allogeneic MHC and antigen induce T cells with superior antitumor activity and higher TCR functional avidity. Blood. 2009;114(10):2131\u20139.","journal-title":"Blood"},{"issue":"4","key":"1408_CR19","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1111\/j.1365-3083.2008.02223.x","volume":"69","author":"E Stronen","year":"2009","unstructured":"Stronen E, Abrahamsen IW, Gaudernack G, W\u00e4lchli S, Munthe E, Buus S, et al. Dendritic cells engineered to express defined allo-HLA peptide complexes induce antigen-specific cytotoxic T cells efficiently killing tumour cells. Scand J Immunol. 2009;69(4):319\u201328.","journal-title":"Scand J Immunol"},{"issue":"12","key":"1408_CR20","doi-asserted-by":"publisher","first-page":"4613","DOI":"10.1182\/blood-2003-11-3903","volume":"103","author":"P Savage","year":"2004","unstructured":"Savage P, Gao L, Vento K, Cowburn P, Man S, Steven N, et al. Use of B cell-bound HLA-A2 class I monomers to generate high-avidity, allo-restricted CTLs against the leukemia-associated protein Wilms tumor antigen. Blood. 2004;103(12):4613\u20135.","journal-title":"Blood"},{"issue":"5961","key":"1408_CR21","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1038\/308741a0","volume":"308","author":"HG Rammensee","year":"1984","unstructured":"Rammensee HG, Bevan MJ. Evidence from in vitro studies that tolerance to self antigens is MHC-restricted. Nature. 1984;308(5961):741\u20134.","journal-title":"Nature"},{"issue":"10","key":"1408_CR22","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1182\/blood-2016-09-737536","volume":"129","author":"L Jahn","year":"2017","unstructured":"Jahn L, Hombrink P, Hagedoorn RS, Kester MG, van der Steen DM, Rodriguez T, et al. TCR-based therapy for multiple myeloma and other B-cell malignancies targeting intracellular transcription factor BOB1. Blood. 2017;129(10):1284\u201395.","journal-title":"Blood"},{"issue":"7","key":"1408_CR23","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1002\/gcc.20668","volume":"48","author":"L Agnelli","year":"2009","unstructured":"Agnelli L, Mosca L, Fabris S, Lionetti M, Andronache A, Kwee I, et al. A SNP microarray and FISH-based procedure to detect allelic imbalances in multiple myeloma: an integrated genomics approach reveals a wide gene dosage effect. Genes Chromosomes Cancer. 2009;48(7):603\u201314.","journal-title":"Genes Chromosomes Cancer"},{"issue":"6","key":"1408_CR24","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1182\/blood-2014-07-587840","volume":"125","author":"L Jahn","year":"2015","unstructured":"Jahn L, Hombrink P, Hassan C, Kester MG, van der Steen DM, Hagedoorn RS, et al. Therapeutic targeting of the BCR-associated protein CD79b in a TCR-based approach is hampered by aberrant expression of CD79b. Blood. 2015;125(6):949\u201358.","journal-title":"Blood"},{"issue":"9","key":"1408_CR25","doi-asserted-by":"publisher","first-page":"3360","DOI":"10.4049\/jimmunol.1700893","volume":"199","author":"V Jurtz","year":"2017","unstructured":"Jurtz V, Paul S, Andreatta M, Marcatili P, Peters B, Nielsen M. NetMHCpan-4.0: improved peptide-MHC class I interaction predictions integrating eluted ligand and peptide binding affinity data. J Immunol. 2017;199(9):3360\u20138.","journal-title":"J Immunol"},{"issue":"11","key":"1408_CR26","doi-asserted-by":"publisher","first-page":"6229","DOI":"10.4049\/jimmunol.165.11.6229","volume":"165","author":"SR Burrows","year":"2000","unstructured":"Burrows SR, Kienzle N, Winterhalter A, Bharadwaj M, Altman JD, Brooks A. Peptide-MHC class I tetrameric complexes display exquisite ligand specificity. J Immunol. 2000;165(11):6229\u201334.","journal-title":"J Immunol"},{"issue":"5","key":"1408_CR27","doi-asserted-by":"publisher","first-page":"e0155165","DOI":"10.1371\/journal.pone.0155165","volume":"11","author":"MJ Pont","year":"2016","unstructured":"Pont MJ, Honders MW, Kremer AN, van Kooten C, Out C, Hiemstra PS, et al. Microarray gene expression analysis to evaluate cell type specific expression of targets relevant for immunotherapy of hematological malignancies. PLoS ONE. 2016;11(5):e0155165.","journal-title":"PLoS ONE"},{"issue":"4","key":"1408_CR28","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/s41408-021-00469-5","volume":"11","author":"PJ Teoh","year":"2021","unstructured":"Teoh PJ, Chng WJ. CAR T-cell therapy in multiple myeloma: more room for improvement. Blood Cancer J. 2021;11(4):84.","journal-title":"Blood Cancer J"},{"issue":"5","key":"1408_CR29","doi-asserted-by":"publisher","first-page":"616","DOI":"10.3324\/haematol.2015.137620","volume":"101","author":"E Drent","year":"2016","unstructured":"Drent E, Groen RWJ, Noort WA, et al. Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma. Haematologica. 2016;101(5):616\u201325.","journal-title":"Haematologica"},{"issue":"26","key":"1408_CR30","doi-asserted-by":"publisher","first-page":"2838","DOI":"10.1182\/blood-2017-04-778423","volume":"130","author":"T Gogishvili","year":"2017","unstructured":"Gogishvili T, Danhof S, Prommersberger S, Rydzek J, Schreder M, Brede C, et al. SLAMF7-CAR T cells eliminate myeloma and confer selective fratricide of SLAMF7(+) normal lymphocytes. Blood. 2017;130(26):2838\u201347.","journal-title":"Blood"},{"issue":"2","key":"1408_CR31","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s11899-017-0373-2","volume":"12","author":"M Ormhoj","year":"2017","unstructured":"Ormhoj M, Bedoya F, Frigault MJ, Maus MV. CARs in the lead against multiple myeloma. Curr Hematol Malig Rep. 2017;12(2):119\u201325.","journal-title":"Curr Hematol Malig Rep"},{"issue":"13","key":"1408_CR32","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1056\/NEJMoa2209900","volume":"387","author":"S Mailankody","year":"2022","unstructured":"Mailankody S, Devlin SM, Landa J, Nath K, Diamonte C, Carstens EJ, et al. GPRC5D-targeted CAR T cells for myeloma. N Engl J Med. 2022;387(13):1196\u2013206.","journal-title":"N Engl J Med"},{"issue":"6","key":"1408_CR33","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1182\/blood-2013-03-490565","volume":"122","author":"GP Linette","year":"2013","unstructured":"Linette GP, Stadtmauer EA, Maus MV, Rapoport AP, Levine BL, Emery L, et al. Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood. 2013;122(6):863\u201371.","journal-title":"Blood"},{"issue":"4","key":"1408_CR34","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/mt.2010.24","volume":"18","author":"RA Morgan","year":"2010","unstructured":"Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther J Am Soc Gene Ther. 2010;18(4):843\u201351.","journal-title":"Mol Ther J Am Soc Gene Ther"},{"key":"1408_CR35","doi-asserted-by":"publisher","DOI":"10.1126\/science.aax9198","author":"M Uhlen","year":"2019","unstructured":"Uhlen M, Karlsson MJ, Zhong W, Tebani A, Pou C, Mikes J, et al. A genome-wide transcriptomic analysis of protein-coding genes in human blood cells. Science. 2019. https:\/\/doi.org\/10.1126\/science.aax9198.","journal-title":"Science"},{"key":"1408_CR36","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abh2169","author":"M Karlsson","year":"2021","unstructured":"Karlsson M, Zhang C, M\u00e9ar L, Zhong W, Digre A, Katona B, et al. A single-cell type transcriptomics map of human tissues. Sci Adv. 2021. https:\/\/doi.org\/10.1126\/sciadv.abh2169.","journal-title":"Sci Adv"},{"issue":"23","key":"1408_CR37","doi-asserted-by":"publisher","first-page":"5290","DOI":"10.1182\/bloodadvances.2021004603","volume":"5","author":"Y Wang","year":"2021","unstructured":"Wang Y, Li C, Xia J, Li P, Cao J, Pan B, et al. Humoral immune reconstitution after anti-BCMA CAR T-cell therapy in relapsed\/refractory multiple myeloma. Blood Adv. 2021;5(23):5290\u20139.","journal-title":"Blood Adv"},{"issue":"8","key":"1408_CR38","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1016\/j.ymthe.2017.04.024","volume":"25","author":"E Drent","year":"2017","unstructured":"Drent E, Themeli M, Poels R, de Jong-Korlaar R, Yuan H, de Bruijn J, et al. A rational strategy for reducing on-target off-tumor effects of CD38-chimeric antigen receptors by affinity optimization. Mol Ther J Am Soc Gene Ther. 2017;25(8):1946\u201358.","journal-title":"Mol Ther J Am Soc Gene Ther"}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-023-01408-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-023-01408-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-023-01408-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,27]],"date-time":"2023-02-27T07:07:37Z","timestamp":1677481657000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-023-01408-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,27]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1408"],"URL":"https:\/\/doi.org\/10.1186\/s13045-023-01408-6","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,27]]},"assertion":[{"value":"17 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Patient and healthy donor materials were collected after written informed consent according to the Declaration of Helsinki. MM patient material from the Leiden University Medical Center Biobank for Hematologic Diseases was used in this study. The study was approved by the Institutional Review Board of the Leiden University Medical Center (approval number 3.4205\/010\/FB\/jr) and the METC-LDD (approval number HEM 008\/SH\/sh).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"JHFF and MHMH are inventors on a filed patent application (patent number P319797NL) \u2018T cell receptors against Jchain and uses thereof.\u2019 The other authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"16"}}